Key result
Tc-99m bone scintigraphy enables early detection and evaluation of transthyretin cardiac amyloidosis.
Why the study?
Cardiac amyloidosis is a rare and mostly underdiagnosed cause of heart failure, and scintigraphic imaging may facilitate early detection and differentiation of cardiac amyloidosis types.
Answers are grounded in this paper and cite their sources.
Tc-99m bisphosphonate scintigraphy may aid early cardiac amyloid detection; leaves open its diagnostic role versus biopsy pending prospective validation.
Amyloidosis is a multisystem disease that results from extracellular deposition of amyloid fibriles in tissue and cardiac involvement may be seen. Cardiac amyloidosis is a rare and mostly underdiagnosed cause of heart failure. Several types of amyloid can infiltrate the myocardium. Diagnosis is usually made with endomyocardial biopsy. Scintigraphic imaging with Technetium (Tc-99m) labelled biphosponates may facilitate early detection of cardiac involvement and distinguish various forms of cardiac amyloidosis. The aim of this guideline is to assist nuclear medicine physicians in recommending, imaging, reporting and interpreting the results of scintigraphy with Tc-99m labelled bone radiopharmaceuticals for the evaluation of transthyretin cardiac amyloidosis.
No takes yet. Share an insight, caveat, or question.
Özdemir et al. (2020) studied Cardiac Transthyretin Amyloidosis. Scintigraphic imaging with Tc-99m labelled bone radiopharmaceuticals was evaluated. Scintigraphic imaging with Tc-99m labelled bone radiopharmaceuticals is recommended to facilitate the early detection and evaluation of transthyretin cardiac amyloidosis.
Synapse has enriched 10 related papers. Consider them for comparative context: